75A50124C00046↗
Cerus Corporation received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $65.36M obligated so far for drugs and biologicals. It runs to 2031-09-30.
Key facts · data as of Oct 22, 2026
- Recipient
- Cerus Corporation
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Obligated to date
- $65.36M
- Potential value
- $209.04M
- Ends
- 2031-09-30
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award 75A50124C00046, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_75A50124C00046_7505_-NONE-_-NONE-
Cerus Corporation: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
LICENSE PATHOGEN REDUCTION TECHNOLOGY (PRT) FOR RED BLOOD CELL (RBC) COMPONENTS TO REDUCE THE RISK OF TRANSFUSION-TRANSMITTED INFECTION (TTI) BY RECOGNIZED, EMERGING, EPIDEMIC, AND ENDEMIC PATHOGENS THAT IS CAPABLE OF TREATING OVER 10 MILLION RBC COM
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Research and Development in Biotechnology (Except Nanobiotechnology) (NAICS 541714)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Cost sharing
- How it was bought
- Standalone contract
- Solicitation
- BAA-23-100-SOL-00004
- Where the work is
- Contra Costa, CA · district CA-10
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
4 actions since 2024-09-20. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-07-21 | P00003 | Supplemental agreement (work within scope) | $33.24M | SUPPLEMENTAL FUNDING TO THE BASE PERIOD (CLIN 0001, CLIN 0002 & CLIN 0003); EXERCISE OPTION 1 (CLIN 0004); UPDATE TRAVEL BUDGET; UPDATE GO/NO-GO MILESTONES; UPDATE INDIRECT RATES; UPDATE COA THRESHOLD TO $350,000; INCORPORATE MANDATORY CLAUSES AS |
| 2025-03-24 | P00002 | Administrative change | $0 | CERUS - NO-COST MODIFICATION IS TO UPDATE ARTICLE G.2. CONTRACTING OFFICER TO ADD JULIE BERGMANN AS THE ALTERNATE CONTRACTING OFFICER'S REPRESENTATIVE (ACOR), UPDATE ARTICLE G.7 INDIRECT COST RATES, AND UPDATE CONTRACT CLAUSES PER EXECUTIVE ORDE |
| 2025-01-21 | P00001 | Supplemental agreement (work within scope) | $0 | NO-COST MODIFICATION IS TO UPDATE ARTICLE G.1. CONTRACTING OFFICER TO REFLECT RICHARD A. HALL AS THE CONTRACTING OFFICER. |
| 2024-09-20 | 0 | $32.12M | LICENSE PATHOGEN REDUCTION TECHNOLOGY (PRT) FOR RED BLOOD CELL (RBC) COMPONENTS TO REDUCE THE RISK OF TRANSFUSION-TRANSMITTED INFECTION (TTI) BY RECOGNIZED, EMERGING, EPIDEMIC, AND ENDEMIC PATHOGENS THAT IS CAPABLE OF TREATING OVER 10 MILLION RBC COM |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗